NCT05380635Phase 2Completed

PK and ECG Determinations Following 8 Weeks of HyBryte Treatment for Cutaneous T-Cell Lymphoma

Study sponsor: Soligenix

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2022-08-16Actual

Enrollment · participants9Actual

Source updated2023-06-07Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Study details

Conditions studied

Cutaneous T-Cell Lymphoma/Mycosis Fungoides

Treatments or interventions studied

HypericinDrugAlso known as HyBryte, SGX301

Primary outcomes · main study measures

measure: Electrocardiograms (ECG); description: Assess any ECG QT interval changes (defined as any occurrences of QT interval \>500 ms or changes in QT interval \>60 ms) during standard HyBryte photodynamic therapy.; timeFrame: 10 weeks; measure: Systemic Blood Levels; description: Assess the systemic blood levels of hypericin during standard HyBryte photodynamic therapy.; timeFrame: 10 weeks

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history